Cargando…
Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
Thus far, only 5–15% of AML patients aged ≥60 years are cured with chemotherapy. Identification of patients who are less (more) likely to respond to standard chemotherapy might enable early risk stratification toward alternative treatment regimens. We used a next-generation sequencing panel of 80 ca...
Autores principales: | Eisfeld, Ann-Kathrin, Kohlschmidt, Jessica, Mrózek, Krzysztof, Blachly, James S., Walker, Christopher J., Nicolet, Deedra, Orwick, Shelley, Maharry, Sophia E., Carroll, Andrew J., Stone, Richard M., de la Chapelle, Albert, Wang, Eunice S., Kolitz, Jonathan E., Powell, Bayard L., Byrd, John C., Bloomfield, Clara D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992022/ https://www.ncbi.nlm.nih.gov/pubmed/29563537 http://dx.doi.org/10.1038/s41375-018-0068-2 |
Ejemplares similares
-
NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome
por: Eisfeld, Ann-Kathrin, et al.
Publicado: (2018) -
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study
por: Bhatnagar, Bhavana, et al.
Publicado: (2023) -
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
por: Mrózek, Krzysztof, et al.
Publicado: (2023) -
Association of social deprivation with survival in younger adult patients with AML: an Alliance study
por: Rebechi, Melanie, et al.
Publicado: (2023) -
Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
por: Fobare, Sydney, et al.
Publicado: (2022)